Quick Answer American Drive Acquisition Co reported Stockholders Equity of -$8.29 million for fiscal year 2025. American Drive Acquisition Co Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 -$8.29M — 2025 $0.00 — Quarterly Stockholders Equity Quarter Ending Stockholders Equity YoY QoQ September 30, 2025 -$6.3K — — June 30, 2025 … Read more
Quick Answer American Drive Acquisition Co reported Total Assets of $231.65 million for fiscal year 2025. American Drive Acquisition Co — Key Financials by Year Metric 2025 Total Assets $231.65M Stockholders Equity $0.00 Most Recent Quarter Metric Quarter Ending Value YoY QoQ Net Income September 30, 2025 -$31.3K — — Total Assets September 30, 2025 … Read more
Quick Answer American Drive Acquisition Co reported Total Assets of $231.65 million for fiscal year 2025. American Drive Acquisition Co Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $231.65M — Quarterly Total Assets Quarter Ending Total Assets YoY QoQ September 30, 2025 $124.6K — — The most recent figure is from … Read more
Quick Answer Acurx Pharmaceuticals, Inc. reported Shares Outstanding of 2.35 million shares for fiscal year 2025. Acurx Pharmaceuticals, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 2.35M +175.8% 2024 851,534 -94.1% 2023 14.47M +24.4% 2022 11.63M +13.8% 2021 10.22M — Quarterly Shares Outstanding Quarter Ending Shares Outstanding YoY QoQ September … Read more
Quick Answer Acurx Pharmaceuticals, Inc. reported Operating Income of -$8.09 million for fiscal year 2025. Acurx Pharmaceuticals, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$8.09M +42.7% 2024 -$14.12M — Quarterly Operating Income Quarter Ending Operating Income YoY QoQ September 30, 2025 -$2.03M +28.2% +10.6% June 30, 2025 -$2.27M +44.9% … Read more
Quick Answer Acurx Pharmaceuticals, Inc. reported Stockholders Equity of $5.27 million for fiscal year 2025. Acurx Pharmaceuticals, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $5.27M +756.5% 2024 $615.1K -86.8% 2023 $4.67M -36.2% 2022 $7.32M -41.1% 2021 $12.41M +359.4% 2020 $2.70M — Quarterly Stockholders Equity Quarter Ending Stockholders Equity YoY … Read more
Quick Answer Acurx Pharmaceuticals, Inc. reported R&D Expense of $1.83 million for fiscal year 2025. Acurx Pharmaceuticals, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $1.83M -66.1% 2024 $5.40M -10.6% 2023 $6.04M +27.1% 2022 $4.75M +134.2% 2021 $2.03M -7.8% 2020 $2.20M — Quarterly R&D Expense Quarter Ending R&D Expense YoY … Read more
Quick Answer Acurx Pharmaceuticals, Inc. reported Total Assets of $7.69 million for fiscal year 2025. Acurx Pharmaceuticals, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $7.69M +99.3% 2024 $3.86M -50.0% 2023 $7.71M -17.8% 2022 $9.38M -29.3% 2021 $13.25M +311.1% 2020 $3.22M — Quarterly Total Assets Quarter Ending Total Assets YoY … Read more
Quick Answer Acurx Pharmaceuticals, Inc. reported Diluted EPS of $5.32 per share (loss) for fiscal year 2025. Acurx Pharmaceuticals, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$5.32 +69.5% 2024 -$17.45 -1417.4% 2023 -$1.15 -2.7% 2022 -$1.12 +24.8% 2021 -$1.49 -101.4% 2020 -$0.74 — Quarterly Diluted EPS Quarter Ending Diluted … Read more
Quick Answer Acurx Pharmaceuticals, Inc. reported Net Income of -$7.97 million for fiscal year 2025. Acurx Pharmaceuticals, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$7.97M +43.5% 2024 -$14.10M +3.3% 2023 -$14.58M -20.5% 2022 -$12.09M +5.1% 2021 -$12.75M -177.1% 2020 -$4.60M — Quarterly Net Income Quarter Ending Net Income YoY … Read more